Categories: "Neurological Disorders"
Reference #: 2012-031
Parkin is a key regulator in the clearance and ubiquitination of toxic proteins in neurodegenerative disorders like
Alzheimer’s disease (AD), Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS). The present
invention identifies novel approach to regulate Parkin for the treatment of neurodegenerative disorders.
Georgetown researches show that some commercial drugs regulate parkin and promote clearance and
ubiquitination of the toxic proteins that are involved in the neurodegenerative disorders. Thus, the present
invention offers a new use of the existing drugs for the treatment of the neurodegenerative disorders.
Potential new uses of existing therapeutics for the treatment of neurodegenerative disorders including AD, PD and ALS.
- Potential to rescue cells and halt neurodegenerative death in the brain
- Novel approach for the treatment of neurodegenerative disorders
- Employs existing FDA approved drugs and this potentially expedites regulatory approval
Stage of Development
In-vivo studies show promising data on parkin regulation and toxic protein clearance by the drugs. Further studies to ascertain behavioral improvements in AD, PD and ALS are on-going.
“Parkinson-related parkin reduces α-synuclein phosphorylation in a gene transfer model”. Moussa et al., Mol
Neurodegener. 2010 Nov 4; 5:47
“Parkin promotes intracellular Abeta1-42 clearance”. Moussa et al., Hum Mol Genet. 2009 Sep 1; 18(17):3206-16
“The relationship between parkin and protein aggregation in neurodegenerative diseases”. Moussa et al., Front
Psychiatry. 2010 Jun 3; 1:15
“A Cancer Drug May Help Treat Alzheimer's And Other Forms Of Dementia,” Forbes.com
and-dementia/>accessed 2013 May 15
“Potential treatment for Parkinson’s, Alzheimer’s, dementia discovered,” FOXNews.com
discovered/> accessed 2013 May 15
Charbel E. Moussa
U.S. Patent Issued - US20140271668A1